Immunological effects of dimethyl fumarate treatment in blood and CSF of patients with primary progressive MS

J. Talbot*, H. Højsgaard Chow, R. Holm Hansen, M. Rode von Essen, F. Sellebjerg

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

7 Citations (Scopus)
19 Downloads (Pure)

Abstract

Dimethyl fumarate is an efficient therapy used widely in patients with relapsing-remitting multiple sclerosis (RRMS). However, lacking effect of treatment has recently been reported in patients with primary progressive MS (PPMS) (Højsgaard Chow et al., 2021). In order to further analyze the immunological treatment response we investigated the systemic and intrathecal immunological effects of dimethyl fumarate (DMF) treatment in 50 patients with PPMS who participated in a 48-week randomized controlled trial with dimethyl fumarate vs placebo. We found substantial systemic immunomodulatory effects of DMF treatment comparable with those observed in patients with RRMS. However, intrathecal effects were limited and restricted to CD4+ T cells presumably resulting in higher concentrations of intrathecal IL-7.

Original languageEnglish
Article number577756
JournalJournal of Neuroimmunology
Volume361
ISSN0165-5728
DOIs
Publication statusPublished - 2021

Bibliographical note

Publisher Copyright:
© 2021 The Authors

Keywords

  • Cerebrospinal fluid immunology
  • Dimethyl fumarate
  • Flow cytometry
  • Primary progressive multiple sclerosis

Cite this